Evidence map›Paper›PMID 26038758›Full record

ReviewEmerging microbes & infections2014

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC.

Zhenglun Liang, Qunying Mao, Yiping Wang, Changgui Li, Kai Gao, Junzhi Wang

Open access · goldAbstract readReview
In one paragraph

Review in Emerging microbes & infections, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhenglun LiangNational Institutes for Food and Drug Control, Beijing 100050, China.
Qunying MaoNational Institutes for Food and Drug Control, Beijing 100050, China.
Yiping WangNational Institutes for Food and Drug Control, Beijing 100050, China.
Changgui LiNational Institutes for Food and Drug Control, Beijing 100050, China.
Kai GaoNational Institutes for Food and Drug Control, Beijing 100050, China.
Junzhi WangNational Institutes for Food and Drug Control, Beijing 100050, China.
National Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Chinese National Institutes for Food and Drug Control (NIFDC) is the national laboratory responsible for the quality control of pharmaceutical products. In recent years, to ensure the quality of biological products and improve the research and development (R&D) of new biological drugs and vaccines, NIFDC conducted a series of regulatory science studies on key technologies for quality control and evaluation, and established a quality control and evaluation platform for biological drugs and vaccines. These studies accelerated the R&D of the biological drugs and vaccines in China and assured their safety and efficacy. In this paper, NIFDC's duties and achievements in the biological drug and vaccine field are summarized.

Indexed as

biotechnology drugquality controlvaccine

Identifiers

PMID26038758
PMCPMC4185363
OpenAlexW2050583471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.